Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxat
August 19 2008 - 8:30AM
PR Newswire (US)
- Clinical evidence for unique Ranexa(R) mechanism of action - PALO
ALTO, Calif., Aug. 19 /PRNewswire-FirstCall/ -- CV Therapeutics,
Inc. (NASDAQ:CVTX) announced today that the Journal of
Cardiovascular Electrophysiology has published a study of
ranolazine showing that ranolazine significantly (p
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024
